Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1061

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections
Diabetic Foot
Osteomyelitis

Interventions

DRUG: Tigecycline
DRUG: Ertapenem

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer